REVIEW ON INTERNATIONAL COUNCIL FOR HARMONISATION GUIDELINE Q12

Q: How many days will it take for my paper to be published?

The review time for papers is not fixed. However, if the paper is accepted and the author completes the processing charges formalities, the paper will be published within a few working days.

Q: I would like to receive a hard copy of the journal materials. Are there any additional charges?

You can log in to the author portal and pay 500 INR to receive the hard copy materials.

Mrs. Meenakshi. S. Mandavkar; Mr. Atharva R. Sankhe; Miss. Srushti D. Raut; Mr. Varad D. Sangare

REVIEW ON INTERNATIONAL COUNCIL FOR HARMONISATION GUIDELINE Q12

Authors: Mrs. Meenakshi. S. Mandavkar, Mr. Atharva R. Sankhe, Miss. Srushti D. Raut, Mr. Varad D. Sangare

Unique Paper ID: 183334
Volume: 12
Issue: 3
PageNo: 853-860

Keywords: Pharmacy Pharmaceutical Guideline Q12 ICH Regulatory affairs

Abstract:
The pharmaceutical industry operates within a strictly regulated environment to ensure the effectiveness, safety, and quality of pharmaceutical products [9]. The International Council for Harmonization (ICH) Q12 guideline, titled "Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management," provides a structured framework for managing post-approval modifications efficiently and scientifically [4]. Introduced as a supplement to previous ICH guidelines (Q8–Q11), ICH Q12 enhances regulatory flexibility while maintaining rigorous product quality standards [3]. A central component of ICH Q12 is the concept of Established Conditions (ECs), which define critical quality attributes and process parameters requiring regulatory oversight [13]. Additionally, the guideline introduces the Post-Approval Change Management Protocol (PACMP) to support manufacturers in implementing modifications more efficiently and predictably [12]. The Product Lifecycle Management (PLCM) Document further ensures consistency in managing product changes over time by promoting transparent communication with regulatory agencies [16]. The implementation of ICH Q12 varies across global regulatory bodies, and achieving harmonization remains challenging due to differences in regional regulatory expectations [11]. Despite these challenges, ICH Q12 represents a significant advancement in lifecycle management, enabling pharmaceutical companies to adopt continuous improvement strategies without compromising regulatory compliance [8]. This review provides a comprehensive analysis of ICH Q12, discussing its fundamental components, regulatory implications, practical challenges, and overall scope. Furthermore, the guideline's impact on international pharmaceutical operations and its potential to drive innovation while preserving product integrity are critically examined [15].

Download article

email to a friend

Cite This Article

ISSN: 2349-6002
Volume: 12
Issue: 3
PageNo: 853-860

REVIEW ON INTERNATIONAL COUNCIL FOR HARMONISATION GUIDELINE Q12

Available:https://ijirt.org/article?manuscript=183334

13 Jun, 2025

Formulation And Evaluation Pantoprazole Oral Disintegration Tablet For Pediatric Use

16 May, 2025

Hydrogels And Their Medical Applications

09 May, 2025

ADVERSE DRUG REPORTING OF THE BENZODIAZEPINE GROUP

01 May, 2025

Formulation And Evaluation Of Lipbalm

30 Apr, 2025

Avocado Gel: Herbal Solution For Skin Nourishment

24 Apr, 2025

Antidandruff Hair Herbal Gel For Dandruff-Free Hairs

05 Apr, 2025

Formulation And Evaluation Of A Herbal Face Pack Using Natural Ingredients

29 Mar, 2025

FORMULATION OF HERBAL LIP BALM FROM SELENICEREUS UNDATUS

26 Mar, 2025

The Role Of AI In Drug Discovery: Accelerating Pharmacological Innovations

21 Mar, 2025

Hydroxypropyl Methylcellulose (HPMC): As A Multitasking Excipient

Impact Factor
8.01 (Year 2024)

UGC Approved
Journal no 47859

Join Our IPN

IJIRT Partner Network

Submit your research paper and those of your network (friends, colleagues, or peers) through your IPN account, and receive 800 INR for each paper that gets published.

Join Now